Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding

Hee Yeon Kay, Won Dong Kim, Se Jin Hwang, Hueng Sik Choi, Richard K. Gilroy, Yu-Jui Yvonne Wan, Sang Geon Kim

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Aims: The nuclear receptor liver X receptor-α (LXRα) stimulates lipogenesis, leading to steatosis. Nuclear factor erythroid-2-related factor-2 (Nrf2) contributes to cellular defense mechanism by upregulating antioxidant genes, and may protect the liver from injury inflicted by fat accumulation. However, whether Nrf2 affects LXRα activity is unknown. This study investigated the inhibitory role of Nrf2 in hepatic LXRα activity and the molecular basis. Results: A deficiency of Nrf2 enhanced the ability of LXRα agonist to promote hepatic steatosis, as mediated by lipogenic gene induction. In hepatocytes, Nrf2 overexpression repressed gene transactivation by LXR-binding site activation. Consistently, treatment of mice with sulforaphane (an Nrf2 activator) suppressed T0901317-induced lipogenesis, as confirmed by the experiments using hepatocytes. Nrf2 activation promoted deacetylation of farnesoid X receptor (FXR) by competing for p300, leading to FXR-dependent induction of small heterodimer partner (SHP), which was responsible for the repression of LXRα-dependent gene transcription. In human steatotic samples, the transcript levels of LXRα and SREBP-1 inversely correlated with those of Nrf2, FXR, and SHP. Innovation: Our findings offer the mechanism to explain how decrease in Nrf2 activity in hepatic steatosis could contribute to the progression of NAFLD, providing the use of Nrf2 as a molecular biomarker to diagnose NAFLD. As certain antioxidants have the abilities to activate Nrf2, clinicians might utilize the activators of Nrf2 as a new therapeutic approach to prevent and/or treat NAFLD. Conclusion: Nrf2 activation inhibits LXRα activity and LXRα-dependent liver steatosis by competing with FXR for p300, causing FXR activation and FXR-mediated SHP induction. Our findings provide important information on a strategy to prevent and/or treat steatosis.

Original languageEnglish (US)
Pages (from-to)2135-2146
Number of pages12
JournalAntioxidants and Redox Signaling
Volume15
Issue number8
DOIs
StatePublished - Oct 15 2011
Externally publishedYes

Fingerprint

Acetylesterase
Lipogenesis
Liver
Genes
Chemical activation
Hepatocytes
Antioxidants
Liver X Receptors
Fatty Liver
Cytoplasmic and Nuclear Receptors
Transcriptional Activation
Biomarkers
Transcription
Fats
Binding Sites
Innovation

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Physiology
  • Clinical Biochemistry

Cite this

Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. / Kay, Hee Yeon; Kim, Won Dong; Hwang, Se Jin; Choi, Hueng Sik; Gilroy, Richard K.; Wan, Yu-Jui Yvonne; Kim, Sang Geon.

In: Antioxidants and Redox Signaling, Vol. 15, No. 8, 15.10.2011, p. 2135-2146.

Research output: Contribution to journalArticle

Kay, Hee Yeon ; Kim, Won Dong ; Hwang, Se Jin ; Choi, Hueng Sik ; Gilroy, Richard K. ; Wan, Yu-Jui Yvonne ; Kim, Sang Geon. / Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding. In: Antioxidants and Redox Signaling. 2011 ; Vol. 15, No. 8. pp. 2135-2146.
@article{ece0fd9ecf534aee8e3d6b34c93e410b,
title = "Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding",
abstract = "Aims: The nuclear receptor liver X receptor-α (LXRα) stimulates lipogenesis, leading to steatosis. Nuclear factor erythroid-2-related factor-2 (Nrf2) contributes to cellular defense mechanism by upregulating antioxidant genes, and may protect the liver from injury inflicted by fat accumulation. However, whether Nrf2 affects LXRα activity is unknown. This study investigated the inhibitory role of Nrf2 in hepatic LXRα activity and the molecular basis. Results: A deficiency of Nrf2 enhanced the ability of LXRα agonist to promote hepatic steatosis, as mediated by lipogenic gene induction. In hepatocytes, Nrf2 overexpression repressed gene transactivation by LXR-binding site activation. Consistently, treatment of mice with sulforaphane (an Nrf2 activator) suppressed T0901317-induced lipogenesis, as confirmed by the experiments using hepatocytes. Nrf2 activation promoted deacetylation of farnesoid X receptor (FXR) by competing for p300, leading to FXR-dependent induction of small heterodimer partner (SHP), which was responsible for the repression of LXRα-dependent gene transcription. In human steatotic samples, the transcript levels of LXRα and SREBP-1 inversely correlated with those of Nrf2, FXR, and SHP. Innovation: Our findings offer the mechanism to explain how decrease in Nrf2 activity in hepatic steatosis could contribute to the progression of NAFLD, providing the use of Nrf2 as a molecular biomarker to diagnose NAFLD. As certain antioxidants have the abilities to activate Nrf2, clinicians might utilize the activators of Nrf2 as a new therapeutic approach to prevent and/or treat NAFLD. Conclusion: Nrf2 activation inhibits LXRα activity and LXRα-dependent liver steatosis by competing with FXR for p300, causing FXR activation and FXR-mediated SHP induction. Our findings provide important information on a strategy to prevent and/or treat steatosis.",
author = "Kay, {Hee Yeon} and Kim, {Won Dong} and Hwang, {Se Jin} and Choi, {Hueng Sik} and Gilroy, {Richard K.} and Wan, {Yu-Jui Yvonne} and Kim, {Sang Geon}",
year = "2011",
month = "10",
day = "15",
doi = "10.1089/ars.2010.3834",
language = "English (US)",
volume = "15",
pages = "2135--2146",
journal = "Antioxidants and Redox Signaling",
issn = "1523-0864",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding

AU - Kay, Hee Yeon

AU - Kim, Won Dong

AU - Hwang, Se Jin

AU - Choi, Hueng Sik

AU - Gilroy, Richard K.

AU - Wan, Yu-Jui Yvonne

AU - Kim, Sang Geon

PY - 2011/10/15

Y1 - 2011/10/15

N2 - Aims: The nuclear receptor liver X receptor-α (LXRα) stimulates lipogenesis, leading to steatosis. Nuclear factor erythroid-2-related factor-2 (Nrf2) contributes to cellular defense mechanism by upregulating antioxidant genes, and may protect the liver from injury inflicted by fat accumulation. However, whether Nrf2 affects LXRα activity is unknown. This study investigated the inhibitory role of Nrf2 in hepatic LXRα activity and the molecular basis. Results: A deficiency of Nrf2 enhanced the ability of LXRα agonist to promote hepatic steatosis, as mediated by lipogenic gene induction. In hepatocytes, Nrf2 overexpression repressed gene transactivation by LXR-binding site activation. Consistently, treatment of mice with sulforaphane (an Nrf2 activator) suppressed T0901317-induced lipogenesis, as confirmed by the experiments using hepatocytes. Nrf2 activation promoted deacetylation of farnesoid X receptor (FXR) by competing for p300, leading to FXR-dependent induction of small heterodimer partner (SHP), which was responsible for the repression of LXRα-dependent gene transcription. In human steatotic samples, the transcript levels of LXRα and SREBP-1 inversely correlated with those of Nrf2, FXR, and SHP. Innovation: Our findings offer the mechanism to explain how decrease in Nrf2 activity in hepatic steatosis could contribute to the progression of NAFLD, providing the use of Nrf2 as a molecular biomarker to diagnose NAFLD. As certain antioxidants have the abilities to activate Nrf2, clinicians might utilize the activators of Nrf2 as a new therapeutic approach to prevent and/or treat NAFLD. Conclusion: Nrf2 activation inhibits LXRα activity and LXRα-dependent liver steatosis by competing with FXR for p300, causing FXR activation and FXR-mediated SHP induction. Our findings provide important information on a strategy to prevent and/or treat steatosis.

AB - Aims: The nuclear receptor liver X receptor-α (LXRα) stimulates lipogenesis, leading to steatosis. Nuclear factor erythroid-2-related factor-2 (Nrf2) contributes to cellular defense mechanism by upregulating antioxidant genes, and may protect the liver from injury inflicted by fat accumulation. However, whether Nrf2 affects LXRα activity is unknown. This study investigated the inhibitory role of Nrf2 in hepatic LXRα activity and the molecular basis. Results: A deficiency of Nrf2 enhanced the ability of LXRα agonist to promote hepatic steatosis, as mediated by lipogenic gene induction. In hepatocytes, Nrf2 overexpression repressed gene transactivation by LXR-binding site activation. Consistently, treatment of mice with sulforaphane (an Nrf2 activator) suppressed T0901317-induced lipogenesis, as confirmed by the experiments using hepatocytes. Nrf2 activation promoted deacetylation of farnesoid X receptor (FXR) by competing for p300, leading to FXR-dependent induction of small heterodimer partner (SHP), which was responsible for the repression of LXRα-dependent gene transcription. In human steatotic samples, the transcript levels of LXRα and SREBP-1 inversely correlated with those of Nrf2, FXR, and SHP. Innovation: Our findings offer the mechanism to explain how decrease in Nrf2 activity in hepatic steatosis could contribute to the progression of NAFLD, providing the use of Nrf2 as a molecular biomarker to diagnose NAFLD. As certain antioxidants have the abilities to activate Nrf2, clinicians might utilize the activators of Nrf2 as a new therapeutic approach to prevent and/or treat NAFLD. Conclusion: Nrf2 activation inhibits LXRα activity and LXRα-dependent liver steatosis by competing with FXR for p300, causing FXR activation and FXR-mediated SHP induction. Our findings provide important information on a strategy to prevent and/or treat steatosis.

UR - http://www.scopus.com/inward/record.url?scp=80052600141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052600141&partnerID=8YFLogxK

U2 - 10.1089/ars.2010.3834

DO - 10.1089/ars.2010.3834

M3 - Article

VL - 15

SP - 2135

EP - 2146

JO - Antioxidants and Redox Signaling

JF - Antioxidants and Redox Signaling

SN - 1523-0864

IS - 8

ER -